Experience with a third generation recombinant factor VIII concentrate (Advate ® ) for immune tolerance induction in patients with haemophilia A
dc.contributor.author | Valentino, L. A. | en_US |
dc.contributor.author | Recht, M. | en_US |
dc.contributor.author | Dipaola, J. | en_US |
dc.contributor.author | Shapiro, A. D. | en_US |
dc.contributor.author | Pipe, Steven W. | en_US |
dc.contributor.author | Ewing, N. | en_US |
dc.contributor.author | Urgo, J. | en_US |
dc.contributor.author | Bullock, T. | en_US |
dc.contributor.author | Simmons, M. | en_US |
dc.contributor.author | Deguzman, C. | en_US |
dc.date.accessioned | 2010-06-01T20:13:00Z | |
dc.date.available | 2010-06-01T20:13:00Z | |
dc.date.issued | 2009-05 | en_US |
dc.identifier.citation | VALENTINO, L. A.; RECHT, M.; DIPAOLA, J.; SHAPIRO, A. D.; PIPE, S. W.; EWING, N.; URGO, J.; BULLOCK, T.; SIMMONS, M.; DEGUZMAN, C. (2009). "Experience with a third generation recombinant factor VIII concentrate (Advate ® ) for immune tolerance induction in patients with haemophilia A." Haemophilia 15(3): 718-726. <http://hdl.handle.net/2027.42/73338> | en_US |
dc.identifier.issn | 1351-8216 | en_US |
dc.identifier.issn | 1365-2516 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/73338 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19298383&dopt=citation | en_US |
dc.format.extent | 169371 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | © 2009 Blackwell Publishing Ltd | en_US |
dc.subject.other | Advate | en_US |
dc.subject.other | Haemophilia A | en_US |
dc.subject.other | Immune Tolerance Induction | en_US |
dc.subject.other | Inhibitor | en_US |
dc.subject.other | Third-generation Recombinant Factor VIII | en_US |
dc.title | Experience with a third generation recombinant factor VIII concentrate (Advate ® ) for immune tolerance induction in patients with haemophilia A | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | ¶ Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | * Departments of Pediatrics and Internal Medicine, Rush University Medical Center, Chicago, IL, USA | en_US |
dc.contributor.affiliationother | † Hemophilia Center, Phoenix Children’s Hospital, Phoenix, AZ, USA | en_US |
dc.contributor.affiliationother | † Department of Pediatrics, University of Iowa Children’s Hospital, Iowa City, IA, USA | en_US |
dc.contributor.affiliationother | § Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA | en_US |
dc.contributor.affiliationother | ** Division of Pediatrics, City of Hope National Medical Center, Duarte, CA, USA | en_US |
dc.identifier.pmid | 19298383 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/73338/1/j.1365-2516.2008.01960.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2516.2008.01960.x | en_US |
dc.identifier.source | Haemophilia | en_US |
dc.identifier.citedreference | Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. Treatment of Hemophilia. World Federation of Hemophilia: September 2004: no. 34. | en_US |
dc.identifier.citedreference | Brackmann HH, Wallny T. Immune tolerance: high-dose regimen In: Rodriguez-Merchan EC, Lee CA eds. “Inhibitors in Patients with Hemophilia”. Oxford, England: Blackwell Science, Ltd, 2002: 45 – 8. | en_US |
dc.identifier.citedreference | Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558 – 63. | en_US |
dc.identifier.citedreference | Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402 – 6. | en_US |
dc.identifier.citedreference | Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739 – 45. | en_US |
dc.identifier.citedreference | Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167 – 72. | en_US |
dc.identifier.citedreference | Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263 – 5. | en_US |
dc.identifier.citedreference | Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267 – 72. | en_US |
dc.identifier.citedreference | Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648 – 54. | en_US |
dc.identifier.citedreference | Koestenberger M, Raith W, Muntean W. High titre inhibitor after continuous factor VIII administration for surgery in a young infant. Haemophilia 2000; 6: 120. | en_US |
dc.identifier.citedreference | Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46 – 51. | en_US |
dc.identifier.citedreference | Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228 – 36. | en_US |
dc.identifier.citedreference | Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422 – 7. | en_US |
dc.identifier.citedreference | Ingerslev J, Freidman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26 ( Suppl 1 ): 118 – 23. | en_US |
dc.identifier.citedreference | Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187 – 93. | en_US |
dc.identifier.citedreference | Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26: 179 – 88. | en_US |
dc.identifier.citedreference | White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560. | en_US |
dc.identifier.citedreference | Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912 – 8. | en_US |
dc.identifier.citedreference | Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626 – 30. | en_US |
dc.identifier.citedreference | Arkin S, Blei F, Fetten J et al. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000; 11: 255 – 9. | en_US |
dc.identifier.citedreference | Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113 – 9. | en_US |
dc.identifier.citedreference | Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000; 60: 547 – 54. | en_US |
dc.identifier.citedreference | Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77 ( Suppl 1 ): 25 – 7. | en_US |
dc.identifier.citedreference | DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52 – 7. | en_US |
dc.identifier.citedreference | Lenk H. The German Registry of immune tolerance treatment in hemophilia--1999 update. Haematologica 2000; 85: 45 – 7. | en_US |
dc.identifier.citedreference | Baxter Healthcare Corporation. ADVATE: [package insert]. Westlake Village, CA: Baxter Healthcare Corporation, 2006. | en_US |
dc.identifier.citedreference | Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363 – 71. | en_US |
dc.identifier.citedreference | DiMichele DM, Hay CR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006; 4: 2271 – 3. | en_US |
dc.identifier.citedreference | Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259: 65 – 8. | en_US |
dc.identifier.citedreference | Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947 – 50. | en_US |
dc.identifier.citedreference | DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280 – 7. | en_US |
dc.identifier.citedreference | Rothschild C, Gill J, Scharrer I, Bray G. Transient inhibitors in the Recombinate PUP study. Thromb Haemost 2000; 84: 145 – 6. | en_US |
dc.identifier.citedreference | Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med 1990; 323: 1800 – 5. | en_US |
dc.identifier.citedreference | Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428 – 35. | en_US |
dc.identifier.citedreference | Lusher JM, Spira J, Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated B-domain deleted factor VIIII (BBD rFVIII, rVIIISQ) in previously untreated severe hemophilia A patients. Thromb Haemost 1999; 82: 1493. | en_US |
dc.identifier.citedreference | Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594 – 8. | en_US |
dc.identifier.citedreference | IITI. International, Randomised, Controlled Trial of Immune-Tolerance Induction. Available at: http://www.itistudy.com (accessed 12 January 2007). | en_US |
dc.identifier.citedreference | Kurth MAH, DiMichele D, Sexauer C et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50 – 5. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.